LAX-101: Phase III data

Top-line data from the double-blind, U.S. Phase III ANCHOR trial in 702 patients with fasting triglyceride levels of 200-500 mg/dL who were also on background statin therapy showed that once-daily 2 and

Read the full 329 word article

How to gain access

Continue reading with a
two-week free trial.